Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207477 | 1.00 | ALDH1A1 (0.45) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL30255499 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL31701825 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL31334845 | 0.82 | ALDH1A1 (0.45) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL994347 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL29536266 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL29197802 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL29179922 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTLMNATHRB | |
| SCHEMBL10036179 | 0.76 | PDK4 (0.51) | ALDH1A1MAPTLMNAGRM5GRM1 | |
| SCHEMBL29535433 | 0.76 | PDK4 (0.51) | ALDH1A1MAPTLMNAGRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885KMT2A 2151/4885MAPT 1280/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4230/4885KMT2A 1429/4885MAPT 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.